Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-cash Items (2021 - 2025)

Historic Non-cash Items for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $6.6 million.

  • Kiniksa Pharmaceuticals International's Non-cash Items fell 1267.12% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 1267.12%. This contributed to the annual value of $62.3 million for FY2024, which is 1405.41% up from last year.
  • Kiniksa Pharmaceuticals International's Non-cash Items amounted to $6.6 million in Q3 2025, which was down 1267.12% from $7.2 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Non-cash Items peaked at $62.3 million during Q4 2024, and registered a low of $4.4 million during Q1 2021.
  • Moreover, its 5-year median value for Non-cash Items was $7.0 million (2023), whereas its average is $13.6 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Non-cash Items surged by 11833.14% in 2022, and later plummeted by 1267.12% in 2025.
  • Kiniksa Pharmaceuticals International's Non-cash Items (Quarter) stood at $14.9 million in 2021, then soared by 118.33% to $32.6 million in 2022, then soared by 67.47% to $54.7 million in 2023, then increased by 14.05% to $62.3 million in 2024, then crashed by 89.33% to $6.6 million in 2025.
  • Its Non-cash Items stands at $6.6 million for Q3 2025, versus $7.2 million for Q2 2025 and $7.8 million for Q1 2025.